Kyle Carver - 05 Nov 2025 Form 3 Insider Report for Evommune, Inc. (EVMN)

Role: Chief Financial Officer
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Issuer symbol: EVMN
Transactions as of: 05 Nov 2025
Transactions value $: $0
Form type: 3
Date filed: 05 Nov 2025, 20:01
Previous filing: 09 Nov 2021
Next filing: 12 Nov 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Carver Kyle	Chief Financial Officer	C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO	/s/ Gregory S. Moss, Attorney-in-Fact	2025-11-05	0001757072

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	EVMN	Common Stock						72.6K	05 Nov 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	EVMN	Series B Preferred Stock							05 Nov 2025	Common Stock	3.18K		Direct	F2
holding	EVMN	Employee Stock Option (Right to Buy)							05 Nov 2025	Common Stock	118K	$3.07	Direct	F3
holding	EVMN	Employee Stock Option (Right to Buy)							05 Nov 2025	Common Stock	30.8K	$3.58	Direct	F4
holding	EVMN	Employee Stock Option (Right to Buy)							05 Nov 2025	Common Stock	57.6K	$3.84	Direct	F5
holding	EVMN	Employee Stock Option (Right to Buy)							05 Nov 2025	Common Stock	7.14K	$1.71	Direct	F6
holding	EVMN	Employee Stock Option (Right to Buy)							05 Nov 2025	Common Stock	112K	$2.99	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. One fourth (1/4) of the RSUs shall vest on each of December 9, 2025, December 9, 2026, December 9, 2027 and December 9, 2028, subject to the Reporting Person's continuous service through each such vesting date.
F2	The Series B Preferred Stock is convertible into Common Stock on a 1-for-7.8721 basis and has no expiration date. Upon the closing of the Issuer's initial public offering, all shares of Series B Preferred Stock will be converted into shares of Common Stock of the Issuer.
F3	One fourth (1/4) of the shares subject to the option award vested on March 2, 2023 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F4	One fourth (1/4) of the shares subject to the option award vested on January 13, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F5	One fourth (1/4) of the shares subject to the option award vested on May 12, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F6	One fourth (1/4) of the shares subject to the option award vested on December 11, 2024 and the remaining shares subject to the option vested or shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F7	One fourth (1/4) of the shares subject to the option award shall vest on December 9, 2025 and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.